• 1
    Dickins M, Tucker G. Drug disposition: to phenotype or genotype. Int J Pharm Med 2001; 15: 7073; also see:
  • 2
    Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapies. Science 1999; 206: 487491; also see:
  • 3
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 (HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737744.
  • 4
    Haseltine WA. Not quite pharmacogenomics (letter; comment). Nat-Biotechnol 1998; 16: 1295.
  • 5
    In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 11301137.
  • 6
    McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998; 102: 19271932.
  • 7
    Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996; 2: 12401243.
  • 8
    Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural gene. Science 1996; 273: 18561862.
  • 9
    Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722725.
  • 10
    O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 32. Lancet 1997; 349: 1219.
  • 11
    Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzious C. Seroco Study Group. HIV-1 infection in an individual homozygous for CCR5 32. Lancet 1997; 349: 12191220.
  • 12
    Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat-Genet 1999; 22: 168170.
  • 13
    Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 31843188.
  • 14
    Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995999.
  • 15
    Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 94149419.
  • 16
    Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13(1): 2533.
  • 17
    Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334349.
  • 18
    Dewar JC, Wheatley AP, Venn A, Morrison JFJ, Britton J, Hall IP. β2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 1998; 28: 442448.
  • 19
    Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann NY Acad Sci 1999; 884: 99109.
  • 20
    Hutchin T, Cortopassi G. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob Agents Chemother 1994; 38: 25172520.
  • 21
    Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene mgmt and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 13501354.
  • 22
    Roses A. Pharmacogentics and future drug development and delivery. Lancet 2000; 355: 13581361.
  • 23
    Proposed international guidelines on ethical issues in medical genetics and genetic services.